List view / Grid view
8 January 2015 | By DWP Public Relations
Changing demographics, ever-evolving regulatory schemes, political pressure to cut costs and social pressure to improve care has led to strong growth in consulting to the global healthcare sector...
8 January 2015 | By Andrew Lloyd & Associates
Ozenoxacin, a novel bactericidal non-fluorinated quinolone, will complete a second phase III clinical trial in adult and paediatric patients with impetigo in the first quarter of 2015...
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
7 January 2015 | By GlobalData
The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to research and consulting firm GlobalData...
7 January 2015 | By Mundipharma
Mundipharma announced that Targin® (Targinact®, Targiniq®), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for a new indication, as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy...
7 January 2015 | By Photocure
Cevira advances towards Phase 3 for treatment in patients with cervical high grade lesions (HSIL)...
6 January 2015 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use...
5 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration...
19 December 2014 | By Merck
Acquisition expands Merck’s oncology portfolio with novel oral BET inhibitor, OTX015...
19 December 2014 | By Roche
Roche announced top-line results of the Phase III MARIANNE study...
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
17 December 2014 | By Eli Lilly and Company
Eli Lilly and Company has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA(R) (ramucirumab)...
17 December 2014 | By GlobalData
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData...
17 December 2014 | By Selvita
Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has successfully completed its Initial Public Offering...
16 December 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embolic Stroke of Undetermined Source, also called ESUS...
